

Cheng-Yuan Peng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1931177/publications.pdf>

Version: 2024-02-01

115
papers

3,243
citations

218677

26
h-index

168389

53
g-index

117
all docs

117
docs citations

117
times ranked

3557
citing authors

#	ARTICLE	IF	CITATIONS
1	Elbasvir and Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. <i>Annals of Internal Medicine</i> , 2016, 165, 625.	3.9	322
2	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. <i>Lancet</i> , The, 2014, 384, 1597-1605.	13.7	316
3	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. <i>Hepatology</i> , 2011, 54, 91-100.	7.3	188
4	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016, 36, 1755-1764.	3.9	177
5	Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. <i>Journal of Hepatology</i> , 2012, 57, 442-450.	3.7	176
6	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2017, 152, 164-175.e4.	1.3	155
7	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. <i>Gastroenterology</i> , 2018, 154, 989-997.	1.3	97
8	Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. <i>Gastroenterology</i> , 2017, 152, 1372-1382.e2.	1.3	79
9	Increased Incidence of Gastrointestinal Cancers Among Patients With Pyogenic Liver Abscess: A Population-Based Cohort Study. <i>Gastroenterology</i> , 2014, 146, 129-137.e1.	1.3	72
10	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.4	72
11	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1135-1157.	1.7	69
12	Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning. <i>EBioMedicine</i> , 2018, 35, 124-132.	6.1	65
13	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	1.7	60
14	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015, 62, 41-47.	3.7	59
15	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	4.0	58
16	Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 457-467.e21.	4.4	56
17	Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. <i>BMC Gastroenterology</i> , 2012, 12, 105.	2.0	50
18	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	7.3	47

#	ARTICLE	IF	CITATIONS
19	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2015, 62, 1013-1023.	7.3	46
20	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1290-1300.	3.7	43
21	Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. <i>BMC Gastroenterology</i> , 2019, 19, 63.	2.0	42
22	Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. <i>Oncotarget</i> , 2017, 8, 92431-92441.	1.8	41
23	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	4.0	40
24	The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2019, 219, 1624-1633.	4.0	32
25	New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. <i>Scientific Reports</i> , 2017, 7, 3259.	3.3	29
26	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	3.9	29
27	A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. <i>Liver International</i> , 2016, 36, 1101-1107.	3.9	28
28	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Gut</i> , 2022, 71, 176-184.	12.1	28
29	All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a subanalysis in Asian patients from the HALLMARK DUAL study. <i>Liver International</i> , 2016, 36, 1433-1441.	3.9	25
30	Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. <i>Anticancer Research</i> , 2002, 22, 1265-71.	1.1	24
31	Next-Generation Sequencing-Based Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma Predicts Hepatocellular Carcinoma Recurrence. <i>Viruses</i> , 2020, 12, 796.	3.3	23
32	Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1323-1329.	2.8	22
33	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	2.0	21
34	Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C. <i>PLoS ONE</i> , 2018, 13, e0190455.	2.5	21
35	Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. <i>Liver International</i> , 2018, 38, 821-833.	3.9	20
36	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021, 15, 338-349.	4.2	20

#	ARTICLE	IF	CITATIONS
37	Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. <i>Hepatology International</i> , 2020, 14, 317-325.	4.2	19
38	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.4	19
39	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	7.7	17
40	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	3.3	16
41	Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. <i>Journal of Infectious Diseases</i> , 2018, 218, 1075-1084.	4.0	16
42	Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B. <i>Scientific Reports</i> , 2017, 7, 42879.	3.3	15
43	Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1998-2005.	2.8	15
44	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE). <i>Journal of Infectious Diseases</i> , 2019, 220, 557-566.	4.8	15
45	Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 956-964.	1.7	15
46	Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. <i>Hepatology International</i> , 2021, 15, 1421-1430.	4.2	15
47	Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. <i>Liver International</i> , 2016, 36, 954-962.	3.9	14
48	Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection. <i>Nutritional Neuroscience</i> , 2017, 20, 291-296.	3.1	14
49	Proton pump inhibitors increase the risk of cholecystitis: a population-based case-control study. <i>Gut</i> , 2019, 68, 1337-1339.	12.1	14
50	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	4.4	14
51	Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. <i>JGH Open</i> , 2021, 5, 929-940.	1.6	14
52	A combination of the on-treatment FIB-4 and alpha-fetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. <i>Liver International</i> , 2018, 38, 1997-2005.	3.9	13
53	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	4.0	13
54	Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. <i>BMC Gastroenterology</i> , 2016, 16, 50.	2.0	12

#	ARTICLE	IF	CITATIONS
55	Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients With Chronic Hepatitis C After Viral Eradication. <i>Clinical Infectious Diseases</i> , 2020, 70, 114-122.	5.8	12
56	Head-to-Head Comparison between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Quantification in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0140554.	2.5	11
57	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 308-313.	1.7	11
58	Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 442-449.	2.8	11
59	Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-8.	1.5	11
60	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 589-597.	4.0	11
61	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	1.7	11
62	On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1177.	3.7	11
63	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	2.8	10
64	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	10
65	An Index to Predict Ribavirin-Induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C. <i>Hepatitis Monthly</i> , 2015, 15, e27148.	0.2	9
66	Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C. <i>Medicine (United States)</i> , 2016, 95, e4736.	1.0	9
67	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1014-1023.	1.7	9
68	Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. <i>Hepatology International</i> , 2020, 14, 513-520.	4.2	9
69	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , 2021, 3, 100254.	4.9	9
70	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. <i>Liver International</i> , 2021, 41, 2671-2680.	3.9	9
71	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 575-588.	8.9	9
72	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, , .	3.7	9

#	ARTICLE	IF	CITATIONS
73	Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress. <i>Molecular Cancer Research</i> , 2020, 18, molcanres.0777.2019.	3.4	8
74	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	3.3	8
75	On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3758.	3.7	8
76	Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients. <i>Journal of Infectious Diseases</i> , 2022, 225, 1974-1981.	4.0	8
77	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021, 11, 23473.	3.3	8
78	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	2.8	7
79	Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1209-1217.	1.6	7
80	Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. <i>Hepatology International</i> , 2011, 5, 586-596.	4.2	6
81	Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy. <i>Liver International</i> , 2018, 38, 627-635.	3.9	6
82	One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. <i>Hepatology International</i> , 2021, 15, 105-113.	4.2	6
83	Mass spectrometry-based plasma peptide profiling of acute exacerbation in HBeAg-positive chronic hepatitis B. <i>Clinica Chimica Acta</i> , 2011, 412, 2174-2182.	1.1	5
84	Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0137852.	2.5	5
85	Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. <i>Clinical Infectious Diseases</i> , 2022, 75, 453-459.	5.8	5
86	Somatic pain associated with initiation of interferon-alpha (IFN- α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 2, 100035.	2.5	4
87	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5372.	3.3	4
88	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	4.4	4
89	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	4.2	4
90	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. <i>Hepatology International</i> , 2016, 10, 294-301.	4.2	3

#	ARTICLE	IF	CITATIONS
91	Ultrasound-Based Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis B or C. Applied Sciences (Switzerland), 2018, 8, 626.	2.5	3
92	Soehendra stent retriever for dilation of tight biliary and pancreatic duct strictures defying conventional wireâ€­guided endoscopic techniques: Singleâ€­center experiences. Advances in Digestive Medicine, 2020, 7, 22-29.	0.2	3
93	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). Open Forum Infectious Diseases, 2020, 7, ofaa397.	0.9	3
94	Longâ€­term risk of endâ€­stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2247-2254.	2.8	3
95	Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study. American Journal of Cancer Research, 2020, 10, 3882-3895.	1.4	3
96	Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older. Gerontology and Geriatric Medicine, 2019, 5, 233372141881739.	1.5	2
97	Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. PLoS ONE, 2020, 15, e0244293.	2.5	2
98	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4â€­6 infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association, 2022, 121, 1567-1578.	1.7	2
99	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. Viruses, 2022, 14, 333.	3.3	2
100	The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1901-1910.	2.8	2
101	Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B in Taiwan: Short-Term Versus Long-Term. Current Hepatitis Reports, 2013, 12, 181-187.	0.3	1
102	Editorial: a baseline tool for predicting response to peginterferon alfaâ€­2a in <scp>HB</scp>eAgâ€­positive patientsâ€­same score, different outcomes. Alimentary Pharmacology and Therapeutics, 2018, 48, 875-876.	3.7	1
103	Editorial: identifying candidates for pegylated interferon addâ€­on to entecavir therapy in patients with <scp>HB</scp>eAgâ€­positive chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2019, 49, 609-610.	3.7	1
104	Gastric necrosis after nivolumab therapy in a patient with advanced hepatocellular carcinoma. Digestive and Liver Disease, 2020, 53, 1506-1507.	0.9	1
105	Liver and Spleen Stiffness Surveillance Through Elastography During and After <scp>Directâ€­Acting</scp> Antiviral Therapy in Patients With Chronic Hepatitis C. Journal of Ultrasound in Medicine, 2022, 41, 1169-1177.	1.7	1
106	Serum miR-21 correlates with the histological stage of chronic hepatitis B-associated liver fibrosis. International Journal of Clinical and Experimental Pathology, 2019, 12, 3819-3829.	0.5	1
107	Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liverâ€­related complications in patients with chronic hepatitis C receiving directâ€­acting antiviral agents. Journal of Viral Hepatitis, 2022, 29, 785-794.	2.0	1
108	Combined Liver Stiffness and Î²-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C. Canadian Journal of Gastroenterology and Hepatology, 2022, 2022, 1-14.	1.9	1

#	ARTICLE	IF	CITATIONS
109	Onâ€treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Liver International</i> , 2021, 41, 1700-1701.	3.9	0
110	Treatment of Fulminant Autoimmune Hepatitis: Corticosteroid Therapy or Liver Transplantation? A Case Report and Literature Review. <i>Gastroenterology Research</i> , 2011, 4, 231-235.	1.3	0
111	Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon- α plus ribavirin therapy: an observational cohort study. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232110676.	2.5	0
112	Title is missing!. , 2020, 15, e0244293.		0
113	Title is missing!. , 2020, 15, e0244293.		0
114	Title is missing!. , 2020, 15, e0244293.		0
115	Title is missing!. , 2020, 15, e0244293.		0